Your Patients are Our Patients.

Patient Referal Lung Institute

Finally, another option.

Lung disease can be debilitating. As physicians, we know that providing treatment options to your patients is important. Until recently, options to improve the quality of life for your patients with lung disease have been limited.

Now, you can consider stem cell therapy. It is an outpatient, minimally invasive procedure that can be recommended to newly diagnosed patients with lung disease, as well as patients in the final stages of their disease. We commonly treat patients with chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis, and interstitial lung disease including pulmonary fibrosis.

All treatments utilize autologous stem cells, minimizing the risk of rejection and making the entire process safe and easy for the patient.

Treatments are performed on an outpatient basis, over the course of 3 days, with each office visit lasting only 2 to 3 hours.

Unlike many other stem cell procedures, those performed at the Lung Institute are minimally invasive, requiring minimal downtime.

The patient always comes first. Our patient care coordinators serve as the patient’s guide throughout the entire treatment process.

Stem Cell Procedure

We offer two types of stem cell procedures: an IV-only procedure, which utilizes stem cells that have been harvested exclusively via IV, and two hybrid procedures that use stem cells extracted from the blood and stem cells from  bone marrow tissue. The type of procedure recommended to a patient is dependent upon his or her condition and overall health. Follow-up booster treatments are typically advised. This simple three-step process takes place in-office over the course of just a few hours.

There are at least two distinct types of stem cells circulating in the peripheral blood: hematopoietic stem cells and mesenchymal stem cells. Both of these cell types originate in the bone marrow and are released into the bloodstream in small quantities.

Hematopoietic stem cells are able to divide and differentiate into different types of blood cells indefinitely and are the primary type of stem cell found in the blood.

While less abundant in the blood, mesenchymal stem cells have a greater differentiation capacity, able to form many unique types of organ tissue.

After extraction, stem cells are isolated, and then both forms of stem cells are re-administered intravenously.


Bone marrow tissue, holds a large quantity of mesenchymal stem cells.

Mesenchymal stem cells have demonstrated the unique ability to become cells specialized to many different organs. Mesenchymal stem cells are harvested from bone marrow tissue through a minimally invasive aspiration.

Intravenous collection of hematopoietic stem cells and blood-circulating mesenchymal stem cells is performed as well.

Once extracted, all stem cells are isolated in the lab, and then re-administered into the patient through the use of an IV.

Although this process is slightly more invasive than the venous procedure,  the bone marrow procedure is an alternative that has proven to be equitably successful.


Mesenchymal stem cells (MSCs) have been proven to secrete anti-inflammatory cytokines.1 These immunosuppressive molecules can facilitate tissue healing and maintain immune homeostasis.2

1Buul, G.m. Van, E. Villafuertes, P.k. Bos, J.h. Waarsing, N. Kops, R. Narcisi, H. Weinans, J.a.n. Verhaar, M.r. Bernsen, and G.j.v.m. Van Osch. “Mesenchymal Stem Cells Secrete Factors That Inhibit Inflammatory Processes in Short-term Osteoarthritic Synovium and Cartilage Explant Culture.” Osteoarthritis and Cartilage 20.10 (2012): 1186-196. Print. 2Thomas, E. Donnall, Karl G. Blume, Stephen J. Forman, and Frederick R. Appelbaum. Thomas’ Hematopoietic Cell Transplantation. Malden, MA, USA: Blackwell Pub., 2004. Print.


Recent data provides evidence that the majority of administered stem cells and progenitor cells are initially trapped in the lungs, particularly when MSCs are delivered through intravenous infusion.3

3Fischer, Uwe M., Matthew T. Harting, Fernando Jimenez, Werner O. Monzon-Posadas, Hasen Xue, Sean I. Savitz, Glen A. Laine, and Charles S. Cox. “Pulmonary Passage Is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect.” Stem Cells and Development18.5 (2009): 683-92. Print.


The immunoregulatory properties and tissue healing functions of MSCs are induced by inflammatory cytokines.4 Research supports that MSCs migrate to sites of tissue injury within the body presumably due to the local production of inflammatory mediators.

4Ma, S., N. Xie, W. Li, B. Yuan, Y. Shi, and Y. Wang. “Immunobiology of Mesenchymal Stem Cells.” Cell Death and Differentiation (2013): n. pag. Print.


One of the undisputed features of MSCs is their ability to produce a variety of trophic and immunomodulatory factors that can directly promote cell survival and reduce inflammation.

We offer two types of stem cell procedures: an IV-only procedure, which utilizes stem cells that have been exclusively derived intravenously and a hybrid procedure that uses stem cells extracted from the blood and stem cells extracted from bone marrow fluid. The type of procedure recommended to a patient is dependent upon his or her condition and overall health. Follow-up booster treatments are typically advised. This simple three-step process takes place in-office over the course of just a few hours.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.